Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Opdiva

Bristol Myers Squibb logo

BMS’ Opdivo/Yervoy combo scores in front-line lung cancer

Makes case for duo therapy in NSCLC patients

- PMLiVE

SMC approves Yescarta and Keytruda, rejects Perjeta

Cancer drugs lead the latest round of recommendations

- PMLiVE

BMS plugs on with Opdivo plus Yervoy in first-line NSCLC

Could be an alternative treatment option to chemotherapy

- PMLiVE

Breath test could predict response to immunotherapy

Study found device accurately predicted responses in lung cancer

Roche Basel Switzerland

Roche scores EU approval twice for Tecentriq in lung cancer

Carves out space in a market dominated by MSD's Keytruda

- PMLiVE

MSD’s Keytruda catches up in kidney cancer

Combination therapy approved in EU for all risk groups

- PMLiVE

Amgen snaps up Celgene’s Otezla for $13.4bn

Higher-than-expected price helps BMS sweeten merger deal

- PMLiVE

Keytruda now available for untreated metastatic lung cancer patients via Cancer Drugs Fund

Proves continuing dominance in this indication

- PMLiVE

Keytruda scores in neoadjuvant triple negative breast cancer combo

Tecentriq still in pole position

Bristol Myers Squibb logo

Opdivo trial overshadows BMS financial results

Hope remains in Celgene merger

- PMLiVE

Celgene cuts back Jounce alliance ahead of BMS merger

Next-gen immuno-oncology alliance lives on

- PMLiVE

Otezla scores new indication as speculation over potential buyers grows

Who will buy blockbuster psoriasis drug?

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links